COMMUNIQUÉS West-GlobeNewswire

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
25/11/2025
Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen Phase 1b AD trial with [...]
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
25/11/2025
WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
Zelluna ASA – Extraordinary General Meeting held on November 25, 2025
25/11/2025
Oslo, November 25, 2025: Zelluna ASA held its extraordinary general meeting today November 25, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and available at the company’s [...]
Adalyon Appoints Ulrik Zeuthen as CEO to Drive Next Phase of Growth in AI-driven Speech-based Biomarkers and Behavioural Analytics for Optimising Clinical Trials
25/11/2025
ESPOO, Finland, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Adalyon, a pioneering tech-bio company using its AI-powered speech biomarker platform to transform clinical drug development, today announced the appointment of Ulrik [...]
Macomics Announces Updated Data of the ENIGMAC Drug Discovery Platform and The Role of Macrophages in Fibrotic Disease
25/11/2025
EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage [...]
Allegro and American Regent sign exclusive licensing deal for SynoglideTM, a novel osteoarthritis treatment in animal health, valued at up to $35 million
25/11/2025
Global license provides American Regent, a wholly owned subsidiary of Daiichi Sankyo, with rights to commercialize Synoglide™ in the veterinary market in most countries of the world. Allegro retains rights to human [...]
RAMSAY SANTE : Press release on November 25 2025
25/11/2025
PRESS RELEASE Paris, 25 th November 2025 Update on Ramsay Health Care Limited's review of its strategic options associated with its majority shareholding in Ramsay Générale de Santé On 27 February 2025, Ramsay Générale [...]
RAMSAY SANTE : communiqué de presse du 25 novembre 2025
25/11/2025
COMMUNIQUÉ DE PRESSE Paris, le 25 novembre 2025 Point sur la revue par Ramsay Health Care Limited de ses options stratégiques concernant sa participation majoritaire dans Ramsay Générale de Santé Le 27 février 2025, [...]
Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
25/11/2025
Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings offer new evidence [...]
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
25/11/2025
Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living [...]
Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025
25/11/2025
Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025 Halle (Saale) / Munich, Germany, November 25 , 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; [...]
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
25/11/2025
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly reduced itch and [...]
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée
25/11/2025
Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Approval based on phase 3 studies showing [...]
Pennsylvania Perio & Implants Announces Strengthened Commitment to Evidence-Based Periodontal and Dental Implant Evaluation in Pennsylvania
25/11/2025
York, Pennsylvania, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Pennsylvania Perio & Implants today announced the reinforcement of its evidence-based framework for periodontal evaluation and dental implant assessment across [...]
Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
25/11/2025
SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy
25/11/2025
Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, [...]
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
25/11/2025
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a [...]
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
24/11/2025
Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studies One-time [...]
Onco360® Has Been Selected as The National Specialty Pharmacy Partner for HYRNUO® (sevabertinib)
24/11/2025
LOUISVILLE, Ky., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Bayer Pharmaceuticals for HYRNUO ® (sevabertinib [...]

Pages